Imiquimod is a synthetic immune response modifier applied topically to the skin. It is used to treat actinic keratosis genital warts and superficial basal cell carcinoma by provoking an innate antiviral response. The drug works by binding to toll-like receptor 7 and 8 on skin cells which triggers the production of type i interferons and pro-inflammatory cytokines. These cytokines activate langerhans cells and stimulate immune cells to recognize and destroy abnormal tissue. The resulting inflammatory process leads to the lesion clearing while preserving surrounding normal skin. Consequently Imiquimod offers a non-surgical therapeutic option that harnesses the body own immune system to eliminate diseased cells.

Imiquimod is a synthetic immune response modifier used topically to treat certain skin conditions. It functions by activating toll-like receptor 7 on skin cells leading to the production of inflammatory cytokines. This activation triggers a local immune response that recruits immune cells and promotes clearance of abnormal tissue. Clinically it is applied to genital warts actinic keratosis and superficial basal cell carcinoma as a non-invasive therapeutic option. The treatment is typically used as a short course and its effects are generally limited to the treated area. Overall Imiquimod provides a mechanism that harnesses the body's innate immunity to remove diseased cells.

Common side effects include mild gastrointestinal discomfort. Headache is frequently reported in many recipients. Fatigue often occurs during the first few days. Injection site reactions such as redness or swelling are typical. Muscle or joint aches may appear shortly after vaccination. Mild fever can develop without indicating serious illness. Nausea and occasional dizziness are observed in some individuals. Most of these effects are short lived and resolve without intervention.

Headaches and mild fever are frequently reported after vaccination. Fatigue and muscle aches are commonly experienced during the first few days. Nausea and occasional loss of appetite may also occur. Swelling at the injection site can appear and usually resolves within a week. Some individuals develop a temporary rash or itching around the injection area. Joint pain and lymph node enlargement are less frequent but documented side effects. Most of these reactions are short-lasting and indicate the body's immune response.